Microbiome Report for Week Ending 12/1/18

Microbiome Report for Week Ending 12/1/18

Source: 
CP Wire
snippet: 

Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced first dosing in its Phase 1b clinical trial of EDP1815 for the treatment of psoriasis and atopic dermatitis.